Actively Recruiting
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Led by University College, London · Updated on 2025-04-02
600
Participants Needed
1
Research Sites
547 weeks
Total Duration
On this page
Sponsors
U
University College, London
Lead Sponsor
C
Cancer Research UK
Collaborating Sponsor
AI-Summary
What this Trial Is About
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
CONDITIONS
Official Title
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent
- Agreement to be followed up every 3 months for the first 2 years and then every 6 months
- Agreement to be followed up at a TRACERx EVO site
- Participants 18 years or older with early stage I-IIIB NSCLC eligible for primary surgery
- Histopathologically confirmed NSCLC or strong suspicion of cancer requiring surgery
- Primary surgery according to NICE guidelines including lobectomy or other lung-sparing or extensive surgeries as needed
- For upfront surgery without neoadjuvant therapy, tumor diameter at least 15mm for sampling
- For neoadjuvant treatment, at least one region of fresh frozen or FFPE surgical or biopsy tissue
- Fit for primary surgery or neoadjuvant therapy with performance status 0 to 2
- Participants 18 years or older with late-stage unresectable stage IIIB and above NSCLC or stage IV metastatic disease
- Sufficient tissue (at least one region/biopsy), either FFPE or fresh frozen
- Fit for anti-cancer treatment with performance status 0 to 2
- Participants 18 years or older with any stage SCLC or pleural mesothelioma
- Sufficient tissue (at least one region/biopsy), either FFPE or fresh frozen
- Fit for anti-cancer treatment with performance status 0 to 2
You will not qualify if you...
- Other active malignancy
- Any other malignancy diagnosed or relapsed currently being treated, including hormonal therapy
- Any malignancy diagnosed or relapsed within the past 3 years except non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer
- Malignancies diagnosed or relapsed 2 to 3 years ago only allowed if lung lesion biopsy confirmed NSCLC
- Psychological condition preventing informed consent
- Diagnosis other than NSCLC, SCLC, or pleural mesothelioma confirmed after surgery or biopsy
- Confirmed diagnosis of high-risk infections such as HIV, HBV, HCV, syphilis, tuberculosis, or Creutzfeldt-Jacob disease unless agreed for scientific interest
- Contraindicated co-morbid conditions
- For Cohort A: positive surgical margins, incomplete resection, or insufficient nodal sampling
- Insufficient tissue for study sampling (less than two tumor regions for upfront surgery or less than one biopsy for neoadjuvant therapy)
- Participants with pre-invasive lesions rather than invasive cancer withdrawn from follow-up but tissue and baseline blood sent for analysis
- For Cohort B/C: insufficient tissue biopsy (less than one region)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University College London Hospitals NHS Foundation Trust
London, United Kingdom, NW1 2PG
Actively Recruiting
Research Team
Z
Zainab Kalokoh
CONTACT
A
Aoife Walker
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here